Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016219 · ClinicalTrials.gov registry record · NA
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
A NA study of Mild Cognitive Impairment, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05016219 is a NA study of Mild Cognitive Impairment that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 120 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05016219, a NA study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his/her assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.
Conditions Studied
Interventions
- DEVICE Circadian-Effective Light
- DEVICE Rhythmic Light
- DEVICE Placebo Light
- DEVICE Placebo Rhythmic Light
Study Locations (2)
New York
- Light and Health Research Center - Menands
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-08-22 |
| Est. Completion | 2027-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016219
The ClinicalTrials.gov registry entry for NCT05016219 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (91% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 4 interventions - of which Circadian-Effective Light is the first listed.
NCT05016219 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05016219 about?
NCT05016219 is a clinical study titled "Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients". Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source th...
What is the current status of trial NCT05016219?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-08-22. Estimated completion is 2027-07-31.
What conditions does trial NCT05016219 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT05016219?
The interventions under investigation include: Circadian-Effective Light (DEVICE), Rhythmic Light (DEVICE), Placebo Light (DEVICE), Placebo Rhythmic Light (DEVICE).
Who is sponsoring clinical trial NCT05016219?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05016219 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Impact of Intensive Computerized Cognitive Training
RECRUITING · NA
-
Multimodal Investigation of Neural Plasticity
RECRUITING · NA
-
GAMES Intervention in MCI (Mild Cognitive Impairment)
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.